Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial
暂无分享，去创建一个
W. Scheithauer | P. Wirapati | V. Heinemann | S. Tejpar | T. Decker | H. Lenz | A. Kiani | D. Aderka | S. Al-Batran | T. Kirchner | A. Jung | D. Neureiter | S. Stintzing | F. Kullmann | L. Fischer von Weikersthal | M. Moehler | T. Heintges | G. Seipelt | C. Kahl | D. Modest | L. F. V. Weikersthal | S. Held | F. Kaiser | C. A. Lerchenmuller | C. Lerchenmüller | Salah-Eddin Al-Batran | Frank Kullmann